Morgan Stanley Reiterates Overweight on Sarepta Therapeutics, Maintains $183 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has reiterated an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a price target of $183.
July 14, 2023 | 3:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has reiterated an Overweight rating on Sarepta Therapeutics and maintained a price target of $183.
The reiteration of an Overweight rating by Morgan Stanley indicates a positive outlook for Sarepta Therapeutics. The maintained price target of $183 suggests that the analyst believes the stock has potential for significant upside. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100